Integrating Clopidogrel's First-Pass Effect in a Joint Semi-Physiological Population Pharmacokinetic Model of the Drug and Its Inactive Carboxylic Acid Metabolite

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2024 May 25

PMID 38794348

Authors

Zorica Pejcic

Valentina Topic Vucenovic

Branislava Miljkovic

Katarina M Vucicevic

Affiliations

Soon will be listed here.

Abstract

Clopidogrel (CLO), a pro-drug for preventing thrombotic events, undergoes rapid absorption and extensive metabolism, with approximately 85-90% converted to an inactive carboxylic acid metabolite (CLO-CA) and the remaining to an active thiol (CLO-TH). Few pharmacokinetic models for the drug and its metabolites exist, with most focusing on CLO-TH. Although CLO-CA is inactive, its predominant (compared to its parent drug and metabolites) presence in plasma underscores the importance of characterizing its formation and pharmacokinetic profile. This study aimed to characterize the process of the absorption of CLO and its conversion to CLO-CA via developing a population pharmacokinetic model. Individual participants' data from two bioequivalence studies were utilized. Extensive blood samples were collected at predetermined intervals, including 841 concentrations of CLO and 1149 of CLO-CA. A nonlinear, mixed-effects modelling approach using NONMEM software (v 7.5) was applied. A one-compartment model was chosen for CLO, while a two-compartment proved optimal for CLO-CA. Absorption from the depot compartment was modeled via two transit compartments, incorporating transit rate constants (). A semi-physiological model explained the first-pass effect of CLO, integrating a liver compartment. The estimated mean transit times () for the studies were 0.470 and 0.410 h, respectively. The relative bioavailability for each study's generic medicine compared to the reference were 1.08 and 0.960, respectively. Based on the estimated parameters, the fractions metabolized to inactive metabolites ( and ) were determined to be 87.27% and 86.87% for the two studies, respectively. The appropriateness of the final model was confirmed. Our model offers a robust framework for elucidating the pharmacokinetic profiles of CLO and CLO-CA.

References

Karazniewicz-Lada M, Danielak D, Burchardt P, Kruszyna L, Komosa A, Lesiak M . Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Clin Pharmacokinet. 2013; 53(2):155-64. PMC: 3899497. DOI: 10.1007/s40262-013-0105-2. View

Pejcic Z, Vucicevic K, Garcia-Arieta A, Miljkovic B . Adjusted indirect comparisons to assess bioequivalence between generic clopidogrel products in Serbia. Br J Clin Pharmacol. 2019; 85(9):2059-2065. PMC: 6710521. DOI: 10.1111/bcp.13997. View

Parke J, Holford N, Charles B . A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999; 59(1):19-29. DOI: 10.1016/s0169-2607(98)00098-4. View

Jiang X, Samant S, Lewis J, Horenstein R, Shuldiner A, Yerges-Armstrong L . Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults. Eur J Pharm Sci. 2015; 82:64-78. PMC: 5798599. DOI: 10.1016/j.ejps.2015.10.024. View

Bahrami G, Mohammadi B, Sisakhtnezhad S . High-performance liquid chromatographic determination of inactive carboxylic acid metabolite of clopidogrel in human serum: Application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 864(1-2):168-72. DOI: 10.1016/j.jchromb.2008.01.049. View

Gobburu J, Lawrence J . Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences. Pharm Res. 2002; 19(1):92-8. DOI: 10.1023/a:1013615701857. View

Ernest 2nd C, Small D, Rohatagi S, Salazar D, Wallentin L, Winters K . Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. J Pharmacokinet Pharmacodyn. 2008; 35(6):593-618. DOI: 10.1007/s10928-008-9103-7. View

Filipe A, Almeida S, Franco Spinola A, Neves R, Tanguay M, Jimenez C . Single-dose randomized, open-label, 2-way crossover bioequivalence study of clopidogrel 75 mg tablet in healthy volunteers under fasting conditions. Int J Clin Pharmacol Ther. 2009; 47(3):187-94. DOI: 10.5414/cpp47187. View

Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N . Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 2004; 92(2):311-6. DOI: 10.1160/TH04-02-0105. View

10.

Djebli N, Fabre D, Boulenc X, Fabre G, Sultan E, Hurbin F . Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics. Drug Metab Dispos. 2015; 43(4):510-22. DOI: 10.1124/dmd.114.062596. View

11.

Gibiansky L, Giraudon M, Rayner C, Brennan B, Subramoney V, Robson R . Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment. J Pharmacokinet Pharmacodyn. 2015; 42(3):225-36. DOI: 10.1007/s10928-015-9411-7. View

12.

Jiang X, Samant S, Lesko L, Schmidt S . Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015; 54(2):147-66. PMC: 5677184. DOI: 10.1007/s40262-014-0230-6. View

13.

El Ahmady O, Ibrahim M, Hussein A, Bustami R . Bioequivalence of two oral formulations of clopidogrel tablets in healthy male volunteers. Int J Clin Pharmacol Ther. 2009; 47(12):780-4. DOI: 10.5414/cpp47780. View

14.

Lee J, Hwang Y, Kang W, Seong S, Lim M, Lee H . Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. J Clin Pharmacol. 2011; 52(7):985-95. DOI: 10.1177/0091270011409228. View

15.

Yousef A, Melhem M, Xue B, Arafat T, Reynolds D, Van Wart S . Population pharmacokinetic analysis of clopidogrel in healthy Jordanian subjects with emphasis optimal sampling strategy. Biopharm Drug Dispos. 2013; 34(4):215-26. DOI: 10.1002/bdd.1839. View

16.

Zhang L, Sun H, Liu Y, Lai X, Gong Y, Liu X . Semi-mechanistic population pharmacokinetics analysis reveals distinct CYP2C19 dependency in the bioactivation of vicagrel and clopidogrel to active metabolite M15-2. Eur J Pharm Sci. 2022; 177:106264. DOI: 10.1016/j.ejps.2022.106264. View

17.

Yu H, Steeghs N, Kloth J, de Wit D, van Hasselt J, van Erp N . Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. Br J Clin Pharmacol. 2014; 79(5):809-19. PMC: 4415717. DOI: 10.1111/bcp.12550. View

18.

Danielak D, Karazniewicz-Lada M, Komosa A, Burchardt P, Lesiak M, Kruszyna L . Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite. Eur J Clin Pharmacol. 2017; 73(12):1623-1632. PMC: 5684285. DOI: 10.1007/s00228-017-2334-z. View

19.

Zhu H, Wang X, Gawronski B, Brinda B, Angiolillo D, Markowitz J . Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther. 2013; 344(3):665-72. DOI: 10.1124/jpet.112.201640. View

20.

Bergstrand M, Hooker A, Wallin J, Karlsson M . Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13(2):143-51. PMC: 3085712. DOI: 10.1208/s12248-011-9255-z. View